Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation
Institute for Clinical and Experimental Medicine
Institute for Clinical and Experimental Medicine
Alliance for Clinical Trials in Oncology
St. Joseph's Healthcare Hamilton
National Cancer Institute (NCI)
Fox Chase Cancer Center
University of Rochester
Northside Hospital, Inc.
Case Comprehensive Cancer Center